Positive O
skin O
tests O
in O
late O
reactions O
to O
radiographic O
contrast B
media I
. O

In O
the O
last O
few O
years O
delayed O
reactions O
several O
hours O
after O
the O
injection O
of O
radiographic O
and O
contrast B
materials I
( O
PRC B
) O
have O
been O
described O
with O
increasing O
frequency O
. O

Nociceptin B
/ O
orphanin B
FQ I
and O
nocistatin B
on O
learning O
and O
memory O
impairment O
induced O
by O
scopolamine B
in O
mice O
. O

Nociceptin B
, O
also O
known O
as O
orphanin B
FQ I
, O
is O
an O
endogenous O
ligand O
for O
the O
orphan O
opioid O
receptor O
- O
like O
receptor O
1 O
( O
ORL1 O
) O
and O
involves O
in O
various O
functions O
in O
the O
central O
nervous O
system O
( O
CNS O
) O
. O

The O
present O
study O
was O
designed O
to O
investigate O
whether O
nociceptin B
/ O
orphanin B
FQ I
and O
nocistatin B
could O
modulate O
impairment O
of O
learning O
and O
memory O
induced O
by O
scopolamine B
, O
a O
muscarinic O
cholinergic O
receptor O
antagonist O
, O
using O
spontaneous O
alternation O
of O
Y O
- O
maze O
and O
step O
- O
down O
type O
passive O
avoidance O
tasks O
in O
mice O
. O

Apoptosis O
was O
assessed O
by O
fluorescence O
microscopy O
in O
Hoechst B
33342 I
- O
and O
propidium B
iodide I
stained O
cell O
samples O
. O

Apoptosis O
was O
assessed O
by O
fluorescence O
microscopy O
in O
Hoechst B
33342 I
- O
and O
propidium B
iodide I
stained O
cell O
samples O
. O

Nitric B
oxide I
( O
NO B
) O
has O
been O
shown O
to O
influence O
dopaminergic O
neurotransmission O
in O
the O
striatum O
. O

PURPOSE O
: O
To O
report O
a O
case O
of O
bilateral O
optic O
neuropathy O
in O
a O
patient O
receiving O
tacrolimus B
( O
FK B
506 I
, O
Prograf O
; O
Fujisawa O
USA O
, O
Inc O
, O
Deerfield O
, O
Illinois O
) O
for O
immunosuppression O
after O
orthotropic O
liver O
transplantation O
. O

Attenuation O
of O
nephrotoxicity O
by O
a O
novel O
lipid O
nanosphere O
( O
NS O
- O
718 O
) O
incorporating O
amphotericin B
B I
. O

NS O
- O
718 O
, O
a O
lipid O
nanosphere O
incorporating O
amphotericin B
B I
, O
is O
effective O
against O
pathogenic O
fungi O
and O
has O
low O
toxicity O
. O

We O
compared O
the O
toxicity O
of O
NS O
- O
718 O
with O
that O
of O
Fungizone B
( O
amphotericin B
B I
- I
sodium I
deoxycholate I
; O
D B
- I
AmB I
) O
in O
vitro O
using O
renal O
cell O
cultures O
and O
in O
vivo O
by O
biochemical O
analysis O
, O
histopathological O
study O
of O
the O
kidney O
and O
pharmacokinetic O
study O
of O
amphotericin B
B I
following O
intravenous O
infusion O
of O
the O
formulation O
in O
rats O
. O

Amphotericin B
B I
concentrations O
in O
the O
kidney O
in O
NS O
- O
718 O
- O
treated O
rats O
were O
higher O
than O
those O
in O
D B
- I
AmB I
- O
treated O
rats O
. O

Our O
in O
vitro O
and O
in O
vivo O
results O
suggest O
that O
incorporation O
of O
amphotericin B
B I
into O
lipid O
nanospheres O
of O
NS O
- O
718 O
attenuates O
the O
nephrotoxicity O
of O
amphotericin B
B I
. O

Our O
in O
vitro O
and O
in O
vivo O
results O
suggest O
that O
incorporation O
of O
amphotericin B
B I
into O
lipid O
nanospheres O
of O
NS O
- O
718 O
attenuates O
the O
nephrotoxicity O
of O
amphotericin B
B I
. O

In O
this O
paper O
we O
aim O
to O
draw O
to O
the O
fact O
that O
caution O
is O
needed O
when O
prescribing O
vitamin B
A I
- O
containing O
drugs O
to O
women O
of O
childbearing O
years O
. O

METHODS O
: O
The O
Assessment O
of O
Lisinopril B
and O
Survival O
study O
was O
a O
multicenter O
, O
randomized O
, O
double O
- O
blind O
trial O
in O
which O
patients O
with O
or O
without O
previous O
ACE B
inhibitor I
treatment O
were O
stabilized O
receiving O
medium O
- O
dose O
lisinopril B
( O
12 O
. O
5 O
or O
15 O
. O
0 O
mg O
once O
daily O
[ O
OD O
] O
) O
for O
2 O
to O
4 O
weeks O
and O
then O
randomized O
to O
high O
- O
( O
35 O
. O
0 O
or O
32 O
. O
5 O
mg O
OD O
) O
or O
low O
- O
dose O
( O
5 O
. O
0 O
or O
2 O
. O
5 O
mg O
OD O
) O
groups O
. O

RESULTS O
: O
Of O
405 O
patients O
not O
previously O
receiving O
an O
ACE B
inhibitor I
, O
doses O
in O
only O
4 O
. O
2 O
% O
could O
not O
be O
titrated O
to O
the O
medium O
doses O
required O
for O
randomization O
because O
of O
symptoms O
possibly O
related O
to O
hypotension O
( O
2 O
. O
0 O
% O
) O
or O
because O
of O
renal O
dysfunction O
or O
hyperkalemia O
( O
2 O
. O
3 O
% O
) O
. O

Subgroups O
presumed O
to O
be O
at O
higher O
risk O
for O
ACE B
inhibitor I
intolerance O
( O
blood O
pressure O
, O
< O
120 O
mm O
Hg O
; O
creatinine B
, O
> O
or O
= O
132 O
. O
6 O
micromol O
/ O
L O
[ O
> O
or O
= O
1 O
. O
5 O
mg O
/ O
dL O
] O
; O
age O
, O
> O
or O
= O
70 O
years O
; O
and O
patients O
with O
diabetes O
) O
generally O
tolerated O
the O
high O
- O
dose O
strategy O
. O

CONCLUSIONS O
: O
These O
findings O
demonstrate O
that O
ACE B
inhibitor I
therapy O
in O
most O
patients O
with O
CHF O
can O
be O
successfully O
titrated O
to O
and O
maintained O
at O
high O
doses O
, O
and O
that O
more O
aggressive O
use O
of O
these O
agents O
is O
warranted O
. O

With O
provision O
of O
adequate O
oleic B
acid I
as O
a O
substrate O
for O
the O
isolated O
perfused O
liver O
, O
a O
direct O
relationship O
was O
observed O
between O
dose O
of O
tetracycline B
and O
both O
accumulation O
of O
triglyceride B
in O
the O
liver O
and O
depression O
of O
output O
of O
triglyceride B
by O
livers O
from O
male O
and O
female O
rats O
. O

These O
differences O
between O
the O
sexes O
could O
not O
be O
related O
to O
altered O
disposition O
of O
tetracycline B
or O
altered O
uptake O
of O
oleic B
acid I
. O

A O
comparison O
of O
glyceryl B
trinitrate I
with O
diclofenac B
for O
the O
treatment O
of O
primary O
dysmenorrhea O
: O
an O
open O
, O
randomized O
, O
cross O
- O
over O
trial O
. O

However O
, O
in O
vivo O
and O
in O
vitro O
studies O
have O
demonstrated O
that O
myometrial O
cells O
are O
also O
targets O
of O
the O
relaxant O
effects O
of O
nitric B
oxide I
( O
NO B
) O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
the O
efficacy O
of O
glyceryl B
trinitrate I
( O
GTN B
) O
, O
an O
NO B
donor O
, O
in O
the O
resolution O
of O
primary O
dysmenorrhea O
in O
comparison O
with O
diclofenac B
( O
DCF B
) O
. O

Temocapril B
, O
a O
long O
- O
acting O
non O
- O
SH O
group O
angiotensin B
converting O
enzyme O
inhibitor O
, O
modulates O
glomerular O
injury O
in O
chronic O
puromycin B
aminonucleoside I
nephrosis O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
determine O
whether O
chronic O
administration O
of O
temocapril B
, O
a O
long O
- O
acting O
non O
- O
SH O
group O
angiotensin B
converting O
enzyme O
( O
ACE O
) O
inhibitor O
, O
reduced O
proteinuria O
, O
inhibited O
glomerular O
hypertrophy O
and O
prevented O
glomerulosclerosis O
in O
chronic O
puromycin B
aminonucleoside I
( O
PAN B
) O
- O
induced O
nephrotic O
rats O
. O

Hypoxaemia O
resolved O
quickly O
on O
inhaled O
nitric B
oxide I
therapy O
. O

High O
- O
dose O
5 B
- I
fluorouracil I
/ O
folinic B
acid I
in O
combination O
with O
three O
- O
weekly O
mitomycin B
C I
in O
the O
treatment O
of O
advanced O
gastric O
cancer O
. O

High O
- O
dose O
5 B
- I
fluorouracil I
/ O
folinic B
acid I
in O
combination O
with O
three O
- O
weekly O
mitomycin B
C I
in O
the O
treatment O
of O
advanced O
gastric O
cancer O
. O

BACKGROUND O
: O
The O
24 O
- O
hour O
continuous O
infusion O
of O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
and O
folinic B
acid I
( O
FA B
) O
as O
part O
of O
several O
new O
multidrug O
chemotherapy O
regimens O
in O
advanced O
gastric O
cancer O
( O
AGC O
) O
has O
shown O
to O
be O
effective O
, O
with O
low O
toxicity O
. O

In O
a O
previous O
phase O
II O
study O
with O
3 O
- O
weekly O
bolus O
5 B
- I
FU I
, O
FA B
and O
mitomycin B
C I
( O
MMC B
) O
we O
found O
a O
low O
toxicity O
rate O
and O
response O
rates O
comparable O
to O
those O
of O
regimens O
such O
as O
ELF O
, O
FAM O
or O
FAMTX O
, O
and O
a O
promising O
median O
overall O
survival O
. O

Before O
admission O
, O
he O
had O
been O
taking O
nicergoline B
and O
bendazac B
lysine I
due O
to O
retinal O
vein O
occlusion O
at O
ophthalmologic O
department O
. O

Moreover O
, O
all O
adenosine B
receptor O
agonists O
: O
2 B
- I
p I
- I
( I
2 I
- I
carboxyethyl I
) I
phenethylamino I
- I
5 I
' I
- I
N I
- I
ethylcarboxamidoadenosine I
( O
CGS B
21680 I
) O
, O
A2A O
receptor O
agonist O
, O
N6 B
- I
cyclopentyladenosine I
( O
CPA B
) O
, O
A1 O
receptor O
agonist O
, O
and O
5 B
' I
- I
N I
- I
ethylcarboxamidoadenosine I
( O
NECA B
) O
, O
A2 O
/ O
A1 O
receptor O
agonist O
significantly O
and O
dose O
- O
dependently O
decreased O
cocaine B
- O
induced O
locomotor O
activity O
. O

CPA B
reduced O
cocaine B
action O
at O
the O
doses O
which O
, O
given O
alone O
, O
did O
not O
influence O
motility O
, O
while O
CGS B
21680 I
and O
NECA B
decreased O
the O
action O
of O
cocaine B
at O
the O
doses O
which O
, O
given O
alone O
, O
decreased O
locomotor O
activity O
in O
animals O
. O

In O
addition O
to O
tiaprofenic B
acid I
, O
indomethacin B
has O
been O
reported O
to O
be O
associated O
with O
this O
condition O
. O

When O
compared O
with O
the O
control O
group O
, O
both O
indomethacin B
groups O
revealed O
statistically O
increased O
numbers O
of O
mast O
cells O
in O
the O
mucosa O
( O
P O
< O
0 O
. O
0001 O
) O
and O
penetration O
of O
lanthanum B
nitrate I
through O
intercellular O
areas O
of O
the O
epithelium O
. O

The O
seizures O
were O
successfully O
treated O
with O
sodium B
thiopental I
in O
addition O
to O
succinylcholine B
in O
1 O
patient O
. O

Current O
options O
of O
treatment O
include O
oral O
anticholinergic O
drugs O
, O
the O
topical O
application O
of O
anticholinergics O
or O
aluminum B
chloride I
, O
and O
the O
injection O
of O
botulinum O
toxin O
. O

Six O
stable O
psychiatric O
outpatients O
with O
hyperprolactinemia O
and O
amenorrhea O
/ O
oligomenorrhea O
associated O
with O
their O
neuroleptic B
medications I
were O
treated O
with O
bromocriptine B
. O

Ethacrynic B
acid I
- O
induced O
convulsions O
and O
brain O
neurotransmitters O
in O
mice O
. O

Intracerebroventricular O
injection O
of O
ethacrynic B
acid I
( O
50 O
% O
convulsive O
dose O
; O
50 O
micrograms O
/ O
mouse O
) O
accelerated O
the O
synthesis O
/ O
turnover O
of O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
but O
suppressed O
the O
synthesis O
of O
gamma B
- I
aminobutyric I
acid I
and O
acetylcholine B
in O
mouse O
brain O
. O

These O
effects O
were O
completely O
antagonized O
by O
pretreatment O
with O
a O
glutamate B
/ O
N B
- I
methyl I
- I
D I
- I
aspartate I
antagonist O
, O
aminophosphonovaleric B
acid I
. O

In O
ethacrynic B
acid I
- O
induced O
convulsions O
, O
these O
neurotransmitter O
systems O
may O
be O
differentially O
modulated O
, O
probably O
through O
activation O
of O
glutaminergic O
neurons O
in O
the O
brain O
. O

Phenylalanine B
, O
a O
large O
neutral O
amino B
acid I
( O
LNAA O
) O
competing O
with O
levodopa B
for O
transport O
across O
the O
blood O
- O
brain O
barrier O
, O
reduced O
the O
hypotensive O
and O
antiparkinsonian O
effects O
of O
levodopa B
. O

Northern O
blot O
analysis O
of O
hepatic O
RNA O
revealed O
a O
dose O
- O
dependent O
increase O
in O
the O
expression O
of O
a O
number O
of O
genes O
critical O
for O
fatty B
acid I
oxidation O
, O
lipoprotein O
assembly O
, O
and O
lipid O
transport O
. O

Protective O
effect O
of O
Terminalia B
chebula I
against O
experimental O
myocardial O
injury O
induced O
by O
isoproterenol B
. O

After O
the O
administration O
of O
nifekalant B
hydrochloride I
, O
sustained O
VT O
was O
terminated O
. O

This O
study O
investigated O
the O
expression O
of O
nuclear O
factor O
- O
kappaB O
( O
NF O
- O
kappaB O
) O
, O
mitogen O
- O
activated O
protein O
( O
MAP O
) O
kinases O
and O
macrophages O
in O
the O
renal O
cortex O
and O
structural O
and O
functional O
renal O
changes O
of O
rats O
treated O
with O
gentamicin B
or O
gentamicin B
+ O
pyrrolidine B
dithiocarbamate I
( O
PDTC B
) O
, O
an O
NF O
- O
kappaB O
inhibitor O
. O

Evans B
Blue I
( O
mug O
g O
- O
1 O
of O
brain O
tissue O
) O
was O
greater O
in O
the O
90 O
/ O
HTN O
group O
( O
24 O
. O
4 O
+ O
/ O
- O
6 O
. O
0 O
) O
versus O
the O
control O
group O
( O
12 O
. O
3 O
+ O
/ O
- O
4 O
. O
1 O
) O
, O
which O
was O
in O
turn O
greater O
than O
the O
15 O
/ O
HTN O
group O
( O
7 O
. O
3 O
+ O
/ O
- O
3 O
. O
2 O
) O
. O

The O
QT O
prolongation O
appeared O
to O
respond O
to O
administration O
of O
i O
. O
v O
. O
calcium B
gluconate I
. O

MATERIALS O
AND O
METHODS O
: O
We O
studied O
with O
a O
2 O
. O
5 O
years O
follow O
- O
up O
the O
changes O
in O
plasma O
cholesterols B
( O
C B
) O
, O
triglycerides B
( O
TG B
) O
, O
lipoproteins O
( O
LP O
) O
, O
and O
apolipoproteins O
( O
Apo O
) O
B O
- O
100 O
, O
A O
- O
I O
, O
and O
A O
- O
II O
pro O
fi O
les O
in O
24 O
patients O
of O
mean O
age O
60 O
years O
with O
low O
risk O
prostate O
cancer O
( O
stage O
: O
T1cN0M0 O
, O
Gleason O
score O
: O
2 O
- O
5 O
) O
during O
treatment O
with O
cyproterone B
acetate I
( O
CPA B
) O
without O

BACKGROUND O
: O
Bepridil B
hydrochloride I
( O
Bpd B
) O
has O
attracted O
attention O
as O
an O
effective O
drug O
for O
atrial O
fibrillation O
( O
AF O
) O
and O
atrial O
flutter O
( O
AFL O
) O
. O

Mechanisms O
of O
hypertension O
induced O
by O
nitric B
oxide I
( O
NO B
) O
deficiency O
: O
focus O
on O
venous O
function O
. O

Loss O
of O
endothelial O
cell O
- O
derived O
nitric B
oxide I
( O
NO B
) O
in O
hypertension O
is O
a O
hallmark O
of O
arterial O
dysfunction O
. O

Anticonvulsant O
effect O
of O
eslicarbazepine B
acetate I
( O
BIA B
2 I
- I
093 I
) O
on O
seizures O
induced O
by O
microperfusion O
of O
picrotoxin B
in O
the O
hippocampus O
of O
freely O
moving O
rats O
. O

Eslicarbazepine B
acetate I
( O
BIA B
2 I
- I
093 I
, O
S B
- I
( I
- I
) I
- I
10 I
- I
acetoxy I
- I
10 I
, I
11 I
- I
dihydro I
- I
5H I
- I
dibenzo I
/ I
b I
, I
f I
/ I
azepine I
- I
5 I
- I
carboxamide I
) O
is O
a O
novel O
antiepileptic O
drug O
, O
now O
in O
Phase O
III O
clinical O
trials O
, O
designed O
with O
the O
aim O
of O
improving O
efficacy O
and O
safety O
in O
comparison O
with O
the O
structurally O
related O
drugs O
carbamazepine B
( O
CBZ B
) O
and O
oxcarbazepine B
( O
OXC B
) O
. O

We O
have O
studied O
the O
effects O
of O
oral O
treatment O
with O
eslicarbazepine B
acetate I
on O
a O
whole O
- O
animal O
model O
in O
which O
partial O
seizures O
can O
be O
elicited O
repeatedly O
on O
different O
days O
without O
changes O
in O
threshold O
or O
seizure O
patterns O
. O

No O
adverse O
effects O
of O
eslicarbazepine B
acetate I
were O
observed O
in O
the O
behavioral O
/ O
EEG O
patterns O
studied O
, O
including O
sleep O
/ O
wakefulness O
cycle O
, O
at O
the O
doses O
studied O
. O

Chinese B
herbal I
medicine O
preparations O
are O
widely O
available O
and O
often O
regarded O
by O
the O
public O
as O
natural O
and O
safe O
remedies O
for O
a O
variety O
of O
medical O
conditions O
. O

Nephropathy O
caused O
by O
Chinese B
herbs I
has O
previously O
been O
reported O
, O
usually O
involving O
the O
use O
of O
aristolochic B
acids I
. O

Nephropathy O
caused O
by O
Chinese B
herbs I
has O
previously O
been O
reported O
, O
usually O
involving O
the O
use O
of O
aristolochic B
acids I
. O

We O
report O
a O
23 O
- O
year O
- O
old O
woman O
who O
developed O
acute O
renal O
failure O
following O
prolonged O
use O
of O
a O
proprietary O
Chinese B
herbal I
slimming O
pill O
that O
contained O
anthraquinone B
derivatives O
, O
extracted O
from O
Rhizoma O
Rhei O
( O
rhubarb O
) O
. O

Toxicity O
of O
CAA B
was O
determined O
by O
protein O
content O
, O
cell O
number O
, O
LDH O
release O
, O
trypan B
blue I
exclusion O
assay O
and O
caspase O
- O
3 O
activity O
. O

OBJECTIVE O
: O
To O
review O
the O
natural O
history O
and O
ocular O
and O
systemic O
adverse O
effects O
of O
patients O
taking O
hydroxychloroquine B
sulfate I
who O
attended O
an O
ophthalmic O
screening O
program O
. O

He O
was O
treated O
with O
lidocaine B
50 O
mg O
intravenously O
followed O
by O
infusion O
1500 O
mg O
in O
dextrose B
5 O
% O
/ O
24 O
hour O
and O
potassium B
aspartate I
tablet O
. O

Penicillamine B
- O
related O
lichenoid O
dermatitis O
and O
utility O
of O
zinc B
acetate I
in O
a O
Wilson O
disease O
patient O
with O
hepatic O
presentation O
, O
anxiety O
and O
SPECT O
abnormalities O
. O

During O
the O
follow O
- O
up O
of O
our O
patient O
, O
penicillamine B
was O
interrupted O
after O
the O
appearance O
of O
a O
lichenoid O
dermatitis O
, O
and O
zinc B
acetate I
permitted O
to O
continue O
the O
successful O
treatment O
of O
the O
patient O
without O
side O
- O
effects O
. O

In O
our O
case O
the O
therapy O
with O
zinc B
acetate I
represented O
an O
effective O
treatment O
for O
a O
Wilson O
' O
s O
disease O
patient O
in O
which O
penicillamine B
- O
related O
side O
effects O
appeared O
. O

The O
safety O
of O
the O
zinc B
acetate I
allowed O
us O
to O
avoid O
other O
potentially O
toxic O
chelating O
drugs O
; O
this O
observation O
is O
in O
line O
with O
the O
growing O
evidence O
on O
the O
efficacy O
of O
the O
drug O
in O
the O
treatment O
of O
Wilson O
' O
s O
disease O
. O

The O
patient O
' O
s O
observations O
were O
within O
normal O
limits O
, O
he O
was O
administered O
oxygen B
via O
a O
face O
mask O
and O
glyceryl B
trinitrate I
( O
GTN B
) O
. O

Several O
minutes O
after O
the O
GTN B
the O
patient O
experienced O
a O
sudden O
drop O
in O
blood O
pressure O
and O
heart O
rate O
, O
this O
was O
rectified O
by O
atropine B
sulphate I
and O
a O
fluid O
challenge O
. O

Corneal O
ulcers O
associated O
with O
aerosolized O
crack B
cocaine I
use O
. O

RESULTS O
: O
Four O
patients O
with O
corneal O
ulcers O
associated O
with O
crack B
cocaine I
use O
were O
reviewed O
. O

CONCLUSIONS O
: O
Aerosolized O
crack B
cocaine I
use O
can O
be O
associated O
with O
the O
development O
of O
corneal O
ulcers O
. O

The O
differential O
effects O
of O
bupivacaine B
and O
lidocaine B
on O
prostaglandin B
E2 I
release O
, O
cyclooxygenase O
gene O
expression O
and O
pain O
in O
a O
clinical O
pain O
model O
. O

In O
the O
present O
study O
, O
we O
describe O
the O
proinflammatory O
effects O
of O
bupivacaine B
on O
local O
prostaglandin B
E2 I
( O
PGE2 B
) O
production O
and O
cyclooxygenase O
( O
COX O
) O
gene O
expression O
that O
increases O
postoperative O
pain O
in O
human O
subjects O
. O

After O
extraction O
, O
a O
microdialysis O
probe O
was O
placed O
at O
the O
surgical O
site O
for O
PGE2 B
and O
thromboxane B
B2 I
( O
TXB2 B
) O
measurements O
. O

BACKGROUND O
: O
The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
antihypertensive O
effects O
of O
angiotensin B
II I
type O
- O
1 O
receptor O
blocker O
, O
losartan B
, O
and O
its O
potential O
in O
slowing O
down O
renal O
disease O
progression O
in O
spontaneously O
hypertensive O
rats O
( O
SHR O
) O
with O
adriamycin B
( O
ADR B
) O
nephropathy O
. O

The O
risks O
of O
aprotinin O
and O
tranexamic B
acid I
in O
cardiac O
surgery O
: O
a O
one O
- O
year O
follow O
- O
up O
of O
1188 O
consecutive O
patients O
. O

BACKGROUND O
: O
Our O
aim O
was O
to O
investigate O
postoperative O
complications O
and O
mortality O
after O
administration O
of O
aprotinin O
compared O
to O
tranexamic B
acid I
in O
an O
unselected O
, O
consecutive O
cohort O
. O

During O
the O
first O
5 O
mo O
, O
596 O
patients O
received O
aprotinin O
( O
Group O
A O
) O
; O
in O
the O
next O
5 O
mo O
, O
592 O
patients O
were O
treated O
with O
tranexamic B
acid I
( O
Group O
T O
) O
. O

Administration O
of O
aprotinin O
should O
be O
avoided O
in O
coronary O
artery O
bypass O
graft O
and O
high O
risk O
patients O
, O
whereas O
administration O
of O
tranexamic B
acid I
is O
not O
recommended O
in O
valve O
surgery O
. O

The O
metabolic O
responses O
to O
isoprenaline B
in O
dogs O
( O
an O
increase O
in O
circulating O
glucose B
, O
lactate B
and O
free O
fatty B
acids I
) O
were O
all O
blocked O
by O
( O
- O
) O
- O
propranolol B
. O

( O
+ O
) O
- O
Propranolol B
had O
no O
effect O
on O
fatty B
acid I
mobilization O
but O
significantly O
reduced O
the O
increments O
in O
both O
lactate B
and O
glucose B
. O
4 O
. O

Valproic B
acid I
( O
VPA B
) O
is O
effective O
for O
the O
treatment O
of O
many O
types O
of O
epilepsy O
, O
but O
its O
use O
can O
be O
associated O
with O
an O
increase O
in O
body O
weight O
. O

One O
should O
be O
aware O
of O
the O
side O
effects O
of O
antithyroid B
medications I
. O

Oxidized B
glutathione I
( O
GSSG B
) O
increased O
significantly O
following O
30 O
and O
60 O
min O
of O
reperfusion O
. O

Additionally O
, O
thiobarbituric B
acid I
reactive O
substances O
( O
TBARSs O
) O
and O
superoxide B
production O
were O
measured O
in O
submitochondrial O
particles O
of O
the O
prefrontal O
cortex O
, O
hippocampus O
, O
striatum O
and O
amygdala O
. O

Citrate B
dialysate O
, O
a O
new O
dialysate O
with O
citric B
acid I
can O
be O
used O
for O
anticoagulation O
in O
patients O
who O
cannot O
tolerate O
heparin B
or O
regional O
citrate B
. O

On O
admission O
the O
patient O
was O
taking O
carvedilol B
12 O
mg O
twice O
daily O
, O
warfarin B
2 O
mg O
/ O
day O
, O
folic B
acid I
1 O
mg O
/ O
day O
, O
levothyroxine B
100 O
microg O
/ O
day O
, O
pantoprazole B
40 O
mg O
/ O
day O
, O
paroxetine B
40 O
mg O
/ O
day O
, O
and O
flecainide B
100 O
mg O
twice O
daily O
. O

Smoking O
of O
crack B
cocaine I
as O
a O
risk O
factor O
for O
HIV O
infection O
among O
people O
who O
use O
injection O
drugs O
. O

BACKGROUND O
: O
Little O
is O
known O
about O
the O
possible O
role O
that O
smoking O
crack B
cocaine I
has O
on O
the O
incidence O
of O
HIV O
infection O
. O

Given O
the O
increasing O
use O
of O
crack B
cocaine I
, O
we O
sought O
to O
examine O
whether O
use O
of O
this O
illicit O
drug O
has O
become O
a O
risk O
factor O
for O
HIV O
infection O
. O

To O
determine O
whether O
the O
risk O
of O
HIV O
seroconversion O
among O
daily O
smokers O
of O
crack B
cocaine I
changed O
over O
time O
, O
we O
used O
Cox O
proportional O
hazards O
regression O
and O
divided O
the O
study O
into O
3 O
periods O
: O
May O
1 O
, O
1996 O
- O
Nov O
. O

The O
mean O
proportion O
of O
participants O
who O
reported O
daily O
smoking O
of O
crack B
cocaine I
increased O
from O
11 O
. O
6 O
% O
in O
period O
1 O
to O
39 O
. O
7 O
% O
in O
period O
3 O
. O

After O
adjusting O
for O
potential O
confounders O
, O
we O
found O
that O
the O
risk O
of O
HIV O
seroconversion O
among O
participants O
who O
were O
daily O
smokers O
of O
crack B
cocaine I
increased O
over O
time O
( O
period O
1 O
: O
hazard O
ratio O
[ O
HR O
] O
1 O
. O
03 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
0 O
. O
57 O
- O
1 O
. O
85 O
; O
period O
2 O
: O
HR O
1 O
. O
68 O
, O
95 O
% O
CI O
1 O
. O
01 O
- O
2 O
. O
80 O
; O
and O
period O
3 O
: O
HR O
2 O
. O
74 O
, O
95 O
% O
CI O
1 O
. O
06 O
- O
7 O
. O
11 O
) O
. O

INTERPRETATION O
: O
Smoking O
of O
crack B
cocaine I
was O
found O
to O
be O
an O
independent O
risk O
factor O
for O
HIV O
seroconversion O
among O
people O
who O
were O
injection O
drug O
users O
. O

This O
finding O
points O
to O
the O
urgent O
need O
for O
evidence O
- O
based O
public O
health O
initiatives O
targeted O
at O
people O
who O
smoke O
crack B
cocaine I
. O

Contrast B
medium I
nephrotoxicity O
after O
renal O
artery O
and O
coronary O
angioplasty O
. O

BACKGROUND O
: O
Renal O
dysfunction O
induced O
by O
iodinated O
contrast B
medium I
( O
CM B
) O
administration O
can O
minimize O
the O
benefit O
of O
the O
interventional O
procedure O
in O
patients O
undergoing O
renal O
angioplasty O
( O
PTRA O
) O
. O

The O
role O
of O
nitric B
oxide I
in O
convulsions O
induced O
by O
lindane B
in O
rats O
. O

Nitric B
oxide I
( O
NO B
) O
, O
gaseous O
neurotransmitter O
, O
has O
contradictor O
role O
in O
epileptogenesis O
due O
to O
opposite O
effects O
of O
L B
- I
arginine I
, O
precursor O
of O
NO B
syntheses O
( O
NOS O
) O
, O
and O
L B
- I
NAME I
( O
NOS O
inhibitor O
) O
observed O
in O
different O
epilepsy O
models O
. O

Neurologic O
toxicities O
have O
been O
described O
with O
IT O
- O
methotrexate B
, O
IT O
- O
cytosine B
arabinoside I
and O
IT O
- O
TSPA B
. O

Mefenamic B
acid I
- O
induced O
neutropenia O
and O
renal O
failure O
in O
elderly O
females O
with O
hypothyroidism O
. O

We O
report O
mefenamic B
acid I
- O
induced O
non O
- O
oliguric O
renal O
failure O
and O
severe O
neutropenia O
occurring O
simultaneously O
in O
two O
elderly O
females O
. O

However O
, O
it O
would O
seem O
prudent O
not O
to O
use O
mefenamic B
acid I
in O
hypothyroid O
patients O
until O
the O
hypothyroidism O
has O
been O
corrected O
. O

Etiology O
of O
hypercalcemia O
in O
hemodialysis O
patients O
on O
calcium B
carbonate I
therapy O
. O

Fourteen O
of O
39 O
dialysis O
patients O
( O
36 O
% O
) O
became O
hypercalcemic O
after O
switching O
to O
calcium B
carbonate I
as O
their O
principal O
phosphate B
binder O
. O

CaCO3 B
dosage O
, O
calculated O
dietary O
calcium B
intake O
, O
and O
circulating O
levels O
of O
vitamin B
D I
metabolites O
were O
similar O
in O
both O
groups O
. O

The O
rats O
in O
the O
control O
group O
were O
intraperitoneally O
( O
i O
. O
p O
. O
) O
injected O
with O
0 O
. O
9 O
% O
saline O
( O
4 O
ml O
/ O
kg O
) O
; O
the O
rats O
in O
the O
model O
group O
were O
i O
. O
p O
. O
injected O
with O
CYP B
( O
150 O
mg O
/ O
kg O
) O
; O
and O
the O
rats O
in O
the O
intervention O
group O
were O
i O
. O
p O
. O
injected O
with O
CYP B
with O
subsequently O
perfusion O
of O
bladder O
with O
P2X3 O
and O
NK1 O
receptors O
' O
antagonists O
, O
Suramin B
and O
GR B
82334 I
. O

Patient O
tolerance O
study O
of O
topical O
chlorhexidine B
diphosphanilate I
: O
a O
new O
topical O
agent O
for O
burns O
. O

Chlorhexidine B
phosphanilate I
( O
CHP B
) O
, O
a O
new O
broad O
- O
spectrum O
antimicrobial O
agent O
, O
has O
been O
evaluated O
as O
a O
topical O
burn O
wound O
dressing O
in O
cream O
form O
, O
but O
preliminary O
clinical O
trials O
reported O
that O
it O
was O
painful O
upon O
application O
. O

One O
burn O
site O
was O
treated O
with O
each O
of O
four O
different O
CHP B
concentrations O
, O
from O
0 O
. O
25 O
per O
cent O
to O
2 O
per O
cent O
, O
their O
vehicle O
, O
and O
1 O
per O
cent O
silver B
sulphadiazine I
( O
AgSD B
) O
cream O
, O
an O
antimicrobial O
agent O
frequently O
used O
for O
topical O
treatment O
of O
burn O
wounds O
. O

Pubertal O
exposure O
to O
Bisphenol B
A I
increases O
anxiety O
- O
like O
behavior O
and O
decreases O
acetylcholinesterase O
activity O
of O
hippocampus O
in O
adult O
male O
mice O
. O

The O
negative O
effects O
of O
Bisphenol B
A I
( O
BPA B
) O
on O
neurodevelopment O
and O
behaviors O
have O
been O
well O
established O
. O

The O
subcutaneous O
injection O
of O
isoproterenol B
( O
30 O
mg O
/ O
kg O
) O
into O
rats O
twice O
at O
an O
interval O
of O
24 O
h O
, O
for O
two O
consecutive O
days O
, O
led O
to O
a O
significant O
increase O
in O
serum O
lactate B
dehydrogenase O
, O
creatine B
phosphokinase O
, O
alanine B
transaminase O
, O
aspartate B
transaminase O
, O
and O
angiotensin B
- O
converting O
enzyme O
activities O
, O
total O
cholesterol B
, O
triglycerides B
, O
free O
serum O
fatty B
acid I
, O
cardiac O
tissue O
malondialdehyde B
( O
MDA B
) O
, O
and O
nitric B
oxide I
levels O
and O
a O
significant O
decrease O
in O
levels O
of O

The O
subcutaneous O
injection O
of O
isoproterenol B
( O
30 O
mg O
/ O
kg O
) O
into O
rats O
twice O
at O
an O
interval O
of O
24 O
h O
, O
for O
two O
consecutive O
days O
, O
led O
to O
a O
significant O
increase O
in O
serum O
lactate B
dehydrogenase O
, O
creatine B
phosphokinase O
, O
alanine B
transaminase O
, O
aspartate B
transaminase O
, O
and O
angiotensin B
- O
converting O
enzyme O
activities O
, O
total O
cholesterol B
, O
triglycerides B
, O
free O
serum O
fatty B
acid I
, O
cardiac O
tissue O
malondialdehyde B
( O
MDA B
) O
, O
and O
nitric B
oxide I
levels O
and O
a O
significant O
decrease O
in O
levels O
of O

Comparison O
of O
effects O
of O
isotonic O
sodium B
chloride I
with O
diltiazem B
in O
prevention O
of O
contrast B
- O
induced O
nephropathy O
. O

The O
aim O
of O
this O
study O
is O
to O
investigate O
and O
compare O
the O
protective O
effects O
of O
isotonic O
sodium B
chloride I
with O
sodium B
bicarbonate I
infusion O
and O
isotonic O
sodium B
chloride I
infusion O
with O
diltiazem B
, O
a O
calcium B
channel O
blocker O
, O
in O
preventing O
CIN O
. O

The O
aim O
of O
this O
study O
is O
to O
investigate O
and O
compare O
the O
protective O
effects O
of O
isotonic O
sodium B
chloride I
with O
sodium B
bicarbonate I
infusion O
and O
isotonic O
sodium B
chloride I
infusion O
with O
diltiazem B
, O
a O
calcium B
channel O
blocker O
, O
in O
preventing O
CIN O
. O

The O
aim O
of O
this O
study O
is O
to O
investigate O
and O
compare O
the O
protective O
effects O
of O
isotonic O
sodium B
chloride I
with O
sodium B
bicarbonate I
infusion O
and O
isotonic O
sodium B
chloride I
infusion O
with O
diltiazem B
, O
a O
calcium B
channel O
blocker O
, O
in O
preventing O
CIN O
. O

The O
first O
group O
of O
patients O
was O
administered O
isotonic O
sodium B
chloride I
; O
the O
second O
group O
was O
administered O
a O
solution O
that O
of O
5 O
% O
dextrose B
and O
sodium B
bicarbonate I
, O
while O
the O
third O
group O
was O
administered O
isotonic O
sodium B
chloride I
before O
and O
after O
the O
contrast B
injection O
. O

The O
first O
group O
of O
patients O
was O
administered O
isotonic O
sodium B
chloride I
; O
the O
second O
group O
was O
administered O
a O
solution O
that O
of O
5 O
% O
dextrose B
and O
sodium B
bicarbonate I
, O
while O
the O
third O
group O
was O
administered O
isotonic O
sodium B
chloride I
before O
and O
after O
the O
contrast B
injection O
. O

The O
first O
group O
of O
patients O
was O
administered O
isotonic O
sodium B
chloride I
; O
the O
second O
group O
was O
administered O
a O
solution O
that O
of O
5 O
% O
dextrose B
and O
sodium B
bicarbonate I
, O
while O
the O
third O
group O
was O
administered O
isotonic O
sodium B
chloride I
before O
and O
after O
the O
contrast B
injection O
. O

CONCLUSION O
: O
There O
was O
no O
significant O
difference O
between O
isotonic O
sodium B
chloride I
, O
sodium B
bicarbonate I
and O
isotonic O
sodium B
chloride I
with O
diltiazem B
application O
in O
prevention O
of O
CIN O
. O

CONCLUSION O
: O
There O
was O
no O
significant O
difference O
between O
isotonic O
sodium B
chloride I
, O
sodium B
bicarbonate I
and O
isotonic O
sodium B
chloride I
with O
diltiazem B
application O
in O
prevention O
of O
CIN O
. O

CONCLUSION O
: O
There O
was O
no O
significant O
difference O
between O
isotonic O
sodium B
chloride I
, O
sodium B
bicarbonate I
and O
isotonic O
sodium B
chloride I
with O
diltiazem B
application O
in O
prevention O
of O
CIN O
. O

Tranexamic B
acid I
overdosage O
- O
induced O
generalized O
seizure O
in O
renal O
failure O
. O

Tranexamic B
acid I
( O
TNA B
) O
1 O
g O
8 O
- O
hourly O
was O
administered O
to O
her O
to O
control O
bleeding O
per O
vaginum O
. O

Plasma O
hydrogen B
peroxide I
( O
H2O2 B
) O
concentration O
and O
ferric O
reducing O
antioxidant O
power O
( O
FRAP O
) O
value O
were O
determined O
. O

The O
association O
between O
tranexamic B
acid I
and O
convulsive O
seizures O
after O
cardiac O
surgery O
: O
a O
multivariate O
analysis O
in O
11 O
529 O
patients O
. O

Independent O
predictors O
of O
postoperative O
seizures O
included O
age O
, O
female O
sex O
, O
redo O
cardiac O
surgery O
, O
calcification O
of O
ascending O
aorta O
, O
congestive O
heart O
failure O
, O
deep O
hypothermic O
circulatory O
arrest O
, O
duration O
of O
aortic O
cross O
- O
clamp O
and O
tranexamic B
acid I
. O

When O
tested O
in O
a O
multivariate O
regression O
analysis O
, O
tranexamic B
acid I
was O
a O
strong O
independent O
predictor O
of O
seizures O
( O
OR O
14 O
. O
3 O
, O
95 O
% O
CI O
5 O
. O
5 O
- O
36 O
. O
7 O
; O
p O
< O
0 O
. O
001 O
) O
. O

As O
tranexamic B
acid I
is O
the O
only O
modifiable O
factor O
, O
its O
administration O
, O
particularly O
in O
doses O
exceeding O
80 O
mg O
. O
kg O
( O
- O
1 O
) O
, O
should O
be O
weighed O
against O
the O
risk O
of O
postoperative O
seizures O
. O

On O
the O
test O
day O
( O
day O
10 O
) O
, O
mice O
were O
subjected O
to O
the O
thermal O
sensitivity O
test O
and O
the O
acetic B
acid I
- O
induced O
writhing O
test O
. O

Re B
( O
300 O
mg O
/ O
kg O
) O
inhibited O
OIH O
in O
both O
the O
thermal O
sensitivity O
test O
and O
the O
acetic B
acid I
- O
induced O
writhing O
test O
. O

Furthermore O
, O
Rg1 B
showed O
a O
tendency O
to O
aggravate O
OIH O
in O
the O
acetic B
acid I
- O
induced O
writhing O
test O
. O

Our O
data O
suggested O
that O
the O
ginsenoside B
Re I
, O
but O
not O
Rg1 B
or O
Rb1 B
, O
may O
contribute O
toward O
reversal O
of O
OIH O
. O

Tetrabenazine B
should O
be O
administered O
very O
carefully O
in O
combination O
with O
other O
neuroleptic B
drugs I
, O
particularly O
in O
patients O
with O
a O
worsening O
general O
condition O
. O

Behavioral O
and O
neurochemical O
studies O
in O
mice O
pretreated O
with O
garcinielliptone B
FC I
in O
pilocarpine B
- O
induced O
seizures O
. O

Garcinielliptone B
FC I
( O
GFC B
) O
isolated O
from O
hexanic O
fraction O
seed O
extract O
of O
species O
Platonia O
insignis O
Mart O
. O

The O
present O
study O
aimed O
to O
evaluate O
the O
GFC B
effects O
at O
doses O
of O
25 O
, O
50 O
or O
75 O
mg O
/ O
kg O
on O
seizure O
parameters O
to O
determine O
their O
anticonvulsant O
activity O
and O
its O
effects O
on O
amino B
acid I
( O
r B
- I
aminobutyric I
acid I
( O
GABA B
) O
, O
glutamine B
, O
aspartate B
and O
glutathione B
) O
levels O
as O
well O
as O
on O
acetylcholinesterase O
( O
AChE O
) O
activity O
in O
mice O
hippocampus O
after O
seizures O
. O

A O
46 O
- O
year O
old O
man O
with O
a O
chronic O
hepatitis O
C O
virus O
infection O
received O
triple O
therapy O
with O
ribavirin B
, O
pegylated B
interferon I
and O
telaprevir B
. O

Protocols O
of O
conversion O
from O
cyclosporin B
A I
( O
CsA B
) O
to O
sirolimus B
( O
SRL B
) O
have O
been O
widely O
used O
in O
immunotherapy O
after O
transplantation O
to O
prevent O
CsA B
- O
induced O
nephropathy O
, O
but O
the O
molecular O
mechanisms O
underlying O
these O
protocols O
remain O
nuclear O
. O

Safety O
and O
efficacy O
of O
fluocinolone B
acetonide I
intravitreal O
implant O
( O
0 O
. O
59 O
mg O
) O
in O
birdshot O
retinochoroidopathy O
. O

PURPOSE O
: O
To O
report O
the O
treatment O
outcomes O
of O
the O
fluocinolone B
acetonide I
intravitreal O
implant O
( O
0 O
. O
59 O
mg O
) O
in O
patients O
with O
birdshot O
retinochoroidopathy O
whose O
disease O
is O
refractory O
or O
intolerant O
to O
conventional O
immunomodulatory O
therapy O
. O

Eleven O
patients O
( O
11 O
eyes O
) O
underwent O
surgery O
for O
fluocinolone B
acetonide I
implant O
( O
0 O
. O
59 O
mg O
) O
. O

Treatment O
outcomes O
of O
interest O
were O
noted O
at O
baseline O
, O
before O
fluocinolone B
acetonide I
implant O
, O
and O
then O
at O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
3 O
years O
, O
and O
beyond O
3 O
years O
. O

CONCLUSION O
: O
The O
data O
suggest O
that O
fluocinolone B
acetonide I
implant O
( O
0 O
. O
59 O
mg O
) O
helps O
to O
control O
inflammation O
in O
otherwise O
treatment O
- O
refractory O
cases O
of O
birdshot O
retinochoroidopathy O
. O

OBJECTIVE O
: O
This O
study O
describes O
associations O
of O
ozone B
and O
fine O
particulate B
matter I
with O
Parkinson O
' O
s O
disease O
observed O
among O
farmers O
in O
North O
Carolina O
and O
Iowa O
. O

RESULTS O
: O
We O
observed O
positive O
associations O
of O
Parkinson O
' O
s O
disease O
with O
ozone B
( O
odds O
ratio O
= O
1 O
. O
39 O
; O
95 O
% O
CI O
: O
0 O
. O
98 O
to O
1 O
. O
98 O
) O
and O
fine O
particulate B
matter I
( O
odds O
ratio O
= O
1 O
. O
34 O
; O
95 O
% O
CI O
: O
0 O
. O
93 O
to O
1 O
. O
93 O
) O
in O
North O
Carolina O
but O
not O
in O
Iowa O
. O

Renal O
angiotensin B
II I
receptor O
type O
2 O
( O
AT2R O
) O
gene O
expression O
in O
adult O
offspring O
was O
reduced O
by O
PCE O
, O
whereas O
the O
renal O
angiotensin B
II I
receptor O
type O
1a O
( O
AT1aR O
) O
/ O
AT2R O
expression O
ratio O
was O
increased O
. O

Renal O
angiotensin B
II I
receptor O
type O
2 O
( O
AT2R O
) O
gene O
expression O
in O
adult O
offspring O
was O
reduced O
by O
PCE O
, O
whereas O
the O
renal O
angiotensin B
II I
receptor O
type O
1a O
( O
AT1aR O
) O
/ O
AT2R O
expression O
ratio O
was O
increased O
. O

BACKGROUND O
: O
Millions O
of O
individuals O
worldwide O
, O
particularly O
those O
living O
in O
rural O
and O
developing O
areas O
, O
are O
exposed O
to O
harmful O
levels O
of O
inorganic B
arsenic I
( O
iAs B
) O
in O
their O
drinking O
water O
. O

Inorganic B
As I
exposure O
during O
key O
developmental O
periods O
is O
associated O
with O
a O
variety O
of O
adverse O
health O
effects O
including O
those O
that O
are O
evident O
in O
adulthood O
. O

In O
a O
38 O
- O
year O
- O
old O
male O
patient O
suffering O
from O
a O
severe O
postzosteric O
trigeminal O
neuralgia O
, O
intravenous O
application O
of O
10 O
mg O
biperiden B
lactate I
led O
to O
a O
long O
- O
lasting O
paradoxical O
reaction O
characterized O
by O
considerable O
bradycardia O
, O
dysarthria O
, O
and O
dysphagia O
. O

ACC B
- I
9653 I
and O
phenytoin B
sodium I
have O
equivalent O
anticonvulsant O
activity O
against O
seizures O
induced O
by O
maximal O
electroshock O
( O
MES O
) O
in O
mice O
following O
i O
. O
p O
. O
, O
oral O
, O
or O
i O
. O
v O
. O
administration O
. O

The O
ED50 O
doses O
were O
16 O
mg O
/ O
kg O
for O
i O
. O
v O
. O
ACC B
- I
9653 I
and O
8 O
mg O
/ O
kg O
for O
i O
. O
v O
. O
phenytoin B
sodium I
. O

ACC B
- I
9653 I
and O
phenytoin B
sodium I
have O
similar O
antiarrhythmic O
activity O
against O
ouabain B
- O
induced O
ventricular O
tachycardia O
in O
anesthetized O
dogs O
. O

The O
total O
doses O
of O
ACC B
- I
9653 I
or O
phenytoin B
sodium I
necessary O
to O
convert O
the O
arrhythmia O
to O
a O
normal O
sinus O
rhythm O
were O
24 O
+ O
/ O
- O
6 O
and O
14 O
+ O
/ O
- O
3 O
mg O
/ O
kg O
, O
respectively O
. O

Only O
phenytoin B
sodium I
displayed O
in O
vitro O
antiarrhythmic O
activity O
against O
strophanthidin B
- O
induced O
arrhythmias O
in O
guinea O
pig O
right O
atria O
. O

In O
anesthetized O
dogs O
, O
a O
high O
dose O
of O
ACC B
- I
9653 I
( O
31 O
mg O
/ O
kg O
) O
was O
infused O
over O
15 O
, O
20 O
, O
and O
30 O
min O
and O
the O
responses O
were O
compared O
to O
an O
equimolar O
dose O
of O
phenytoin B
sodium I
( O
21 O
mg O
/ O
kg O
) O
. O

The O
ACC B
- I
9653 I
and O
phenytoin B
sodium I
treatments O
produced O
similar O
marked O
reductions O
in O
diastolic O
blood O
pressure O
and O
contractile O
force O
( O
LVdP O
/ O
dt O
) O
. O

The O
maximum O
effects O
of O
each O
treatment O
occurred O
at O
the O
time O
of O
maximum O
phenytoin B
sodium I
levels O
. O

Acute O
toxicity O
studies O
of O
ACC B
- I
9653 I
and O
phenytoin B
sodium I
were O
carried O
out O
in O
mice O
, O
rats O
, O
rabbits O
, O
and O
dogs O
by O
i O
. O
v O
. O
, O
i O
. O
m O
. O
, O
and O
i O
. O
p O
. O
routes O
of O
administration O
. O

Importantly O
, O
the O
local O
irritation O
of O
ACC B
- I
9653 I
was O
markedly O
less O
than O
phenytoin B
sodium I
following O
i O
. O
m O
. O
administration O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

During O
the O
14 O
- O
day O
run O
- O
in O
and O
during O
washout O
periods O
, O
inhaled O
beta O
- O
agonists O
were O
withheld O
and O
ipratropium B
bromide I
was O
substituted O
for O
rescue O
purposes O
. O

Treatment O
of O
lethal O
pertussis B
vaccine I
reaction O
with O
histamine B
H1 O
antagonists O
. O

However O
, O
any O
improvement O
produced O
by O
drug O
treatment O
was O
largely O
a O
result O
of O
a O
beneficial O
effect O
exerted O
by O
its O
vehicle O
( O
polyethylene B
glycol I
and O
NaOH B
) O
. O

Comparison O
of O
the O
effect O
of O
oxitropium B
bromide I
and O
of O
slow O
- O
release O
theophylline B
on O
nocturnal O
asthma O
. O

The O
effects O
of O
a O
new O
inhaled O
antimuscarinic O
drug O
, O
oxitropium B
bromide I
, O
and O
of O
a O
slow O
- O
release O
theophylline B
preparation O
upon O
nocturnal O
asthma O
were O
compared O
in O
a O
placebo O
- O
controlled O
double O
- O
blind O
study O
. O

Reversible O
valproic B
acid I
- O
induced O
dementia O
: O
a O
case O
report O
. O

Reversible O
valproic B
acid I
- O
induced O
dementia O
was O
documented O
in O
a O
21 O
- O
year O
- O
old O
man O
with O
epilepsy O
who O
had O
a O
3 O
- O
year O
history O
of O
insidious O
progressive O
decline O
in O
global O
cognitive O
abilities O
documented O
by O
serial O
neuropsychological O
studies O
. O

Possible O
pathophysiological O
mechanisms O
which O
may O
have O
been O
operative O
in O
this O
case O
include O
: O
a O
direct O
central O
nervous O
system O
( O
CNS O
) O
toxic O
effect O
of O
valproic B
acid I
; O
a O
paradoxical O
epileptogenic O
effect O
secondary O
to O
the O
drug O
; O
and O
an O
indirect O
CNS O
toxic O
effect O
mediated O
through O
valproic B
acid I
- O
induced O
hyperammonemia O
. O

Possible O
pathophysiological O
mechanisms O
which O
may O
have O
been O
operative O
in O
this O
case O
include O
: O
a O
direct O
central O
nervous O
system O
( O
CNS O
) O
toxic O
effect O
of O
valproic B
acid I
; O
a O
paradoxical O
epileptogenic O
effect O
secondary O
to O
the O
drug O
; O
and O
an O
indirect O
CNS O
toxic O
effect O
mediated O
through O
valproic B
acid I
- O
induced O
hyperammonemia O
. O

Scopolamine B
, O
but O
not O
methyl B
scopolamine I
( O
1 O
and O
3 O
mg O
/ O
kg O
) O
, O
induced O
an O
amnesia O
as O
measured O
by O
latency O
and O
duration O
parameters O
. O

The O
present O
study O
was O
designed O
to O
investigate O
the O
effect O
of O
5 O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
, O
sodium B
salicylate I
, O
phenylbutazone B
, O
indomethacin B
, O
ibuprofen B
and O
mefenamic B
acid I
, O
on O
seizures O
produced O
by O
pilocarpine B
. O

The O
present O
study O
was O
designed O
to O
investigate O
the O
effect O
of O
5 O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
, O
sodium B
salicylate I
, O
phenylbutazone B
, O
indomethacin B
, O
ibuprofen B
and O
mefenamic B
acid I
, O
on O
seizures O
produced O
by O
pilocarpine B
. O

Pretreatment O
of O
rats O
with O
sodium B
salicylate I
, O
ED50 O
103 O
mg O
/ O
kg O
( O
60 O
- O
174 O
) O
, O
and O
phenylbutazone B
, O
59 O
mg O
/ O
kg O
( O
50 O
- O
70 O
) O
converted O
the O
non O
- O
convulsant O
dose O
of O
pilocarpine B
, O
200 O
mg O
/ O
kg O
, O
to O
a O
convulsant O
one O
. O

Mefenamic B
acid I
, O
26 O
( O
22 O
- O
30 O
) O
mg O
/ O
kg O
, O
prevented O
seizures O
and O
protected O
rats O
from O
seizure O
- O
related O
brain O
damage O
induced O
by O
pilocarpine B
, O
380 O
mg O
/ O
kg O
. O

An O
experimental O
model O
of O
focal O
segmental O
glomerular O
sclerosis O
( O
FSGS O
) O
was O
developed O
in O
rats O
by O
the O
combined O
administration O
of O
puromycin B
- I
aminonucleoside I
( O
AMNS B
) O
and O
protamine B
sulfate I
( O
PS B
) O
. O

We O
have O
described O
a O
patient O
with O
severe O
rheumatoid O
arthritis O
and O
a O
history O
of O
mefenamic B
acid I
nephropathy O
in O
whom O
hyperkalemia O
and O
inappropriate O
hypoaldosteronism O
were O
caused O
by O
both O
indomethacin B
and O
naproxen B
, O
without O
major O
decline O
in O
renal O
function O
. O

Rechallenge O
of O
patients O
who O
developed O
oral O
candidiasis O
or O
hoarseness O
with O
beclomethasone B
dipropionate I
. O

Flurothyl B
seizure O
thresholds O
in O
mice O
treated O
neonatally O
with O
a O
single O
injection O
of O
monosodium B
glutamate I
( O
MSG B
) O
: O
evaluation O
of O
experimental O
parameters O
in O
flurothyl B
seizure O
testing O
. O

Monosodium B
glutamate I
( O
MSG B
) O
administration O
to O
neonatal O
rodents O
produces O
convulsions O
and O
results O
in O
numerous O
biochemical O
and O
behavioral O
deficits O
. O

A O
postmarketing O
surveillance O
study O
was O
conducted O
to O
determine O
the O
safety O
and O
efficacy O
of O
a O
fixed O
- O
ratio O
combination O
containing O
10 O
mg O
of O
timolol B
maleate I
and O
25 O
mg O
of O
hydrochlorothiazide B
, O
administered O
twice O
daily O
for O
one O
month O
to O
hypertensive O
patients O
. O

PGF2 B
alpha I
was O
also O
significantly O
higher O
in O
the O
outer O
medulla O
of O
jj O
rats O
with O
and O
without O
aspirin B
administration O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

Cardiovascular O
dysfunction O
and O
hypersensitivity O
to O
sodium B
pentobarbital I
induced O
by O
chronic O
barium B
chloride I
ingestion O
. O

Cardiovascular O
dysfunction O
and O
hypersensitivity O
to O
sodium B
pentobarbital I
induced O
by O
chronic O
barium B
chloride I
ingestion O
. O

The O
most O
distinctive O
aspect O
of O
the O
barium B
effect O
was O
a O
demonstrated O
hypersensitivity O
of O
the O
cardiovascular O
system O
to O
sodium B
pentobarbital I
. O

The O
lack O
of O
a O
similar O
response O
to O
ketamine B
and O
xylazine B
anesthesia O
revealed O
that O
the O
cardiovascular O
actions O
of O
sodium B
pentobarbital I
in O
barium B
- O
treated O
rats O
were O
linked O
specifically O
to O
this O
anesthetic O
, O
and O
were O
not O
representative O
of O
a O
generalized O
anesthetic O
response O
. O

Overall O
, O
the O
altered O
cardiac O
contractility O
and O
excitability O
characteristics O
, O
the O
myocardial O
metabolic O
disturbances O
, O
and O
the O
hypersensitivity O
of O
the O
cardiovascular O
system O
to O
sodium B
pentobarbital I
suggest O
the O
existence O
of O
a O
heretofore O
undescribed O
cardiomyopathic O
disorder O
induced O
by O
chronic O
barium B
exposure O
. O

The O
possible O
relationship O
between O
mesangial O
dysfunction O
and O
development O
of O
glomerular O
sclerosis O
was O
studied O
in O
the O
puromycin B
aminonucleoside I
( O
PAN B
) O
model O
. O

Two O
neonates O
suffered O
from O
generalized O
seizures O
during O
the O
course O
of O
intravenous O
morphine B
sulfate I
for O
post O
- O
operative O
analgesia O
. O

Four O
types O
of O
experimental O
arrhythmia O
are O
used O
- O
- O
with O
BaCl2 B
, O
with O
chloroform B
- O
adrenaline B
, O
with O
strophantine B
G I
and O
with O
aconitine B
. O

Recurrent O
subarachnoid O
hemorrhage O
associated O
with O
aminocaproic B
acid I
therapy O
and O
acute O
renal O
artery O
thrombosis O
. O

Effect O
of O
vincristine B
sulfate I
on O
Pseudomonas O
infections O
in O
monkeys O
. O

Intravenous O
or O
intratracheal O
inoculation O
of O
2 O
. O
0 O
to O
2 O
. O
5 O
mg O
of O
vincristine B
sulfate I
was O
followed O
by O
leukopenia O
in O
4 O
to O
5 O
days O
. O

Intravenous O
inoculation O
of O
4 O
. O
2 O
x O
10 O
( O
10 O
) O
to O
7 O
. O
8 O
x O
10 O
( O
10 O
) O
pyocin O
type O
6 O
Pseudomonas O
organisms O
in O
monkeys O
given O
vincristine B
sulfate I
4 O
days O
previously O
resulted O
in O
fatal O
infection O
in O
11 O
of O
14 O
monkeys O
, O
whereas O
none O
of O
four O
receiving O
Pseudomonas O
alone O
died O
. O

The O
treatment O
schedule O
consisted O
of O
conjugated B
estrogens I
( O
Premarin B
) O
1 O
. O
25 O
mg O
/ O
day O
for O
21 O
days O
and O
Medroxyprogesterone B
acetate I
10 O
mg O
/ O
day O
for O
10 O
days O
in O
each O
month O
. O

The O
treatment O
schedule O
consisted O
of O
conjugated B
estrogens I
( O
Premarin B
) O
1 O
. O
25 O
mg O
/ O
day O
for O
21 O
days O
and O
Medroxyprogesterone B
acetate I
10 O
mg O
/ O
day O
for O
10 O
days O
in O
each O
month O
. O

Intraperitoneal O
administration O
of O
cholecystokinin B
octapeptide I
sulphate O
ester O
( O
CCK B
- I
8 I
- O
SE O
) O
and O
nonsulphated O
cholecystokinin B
octapeptide I
( O
CCK B
- I
8 I
- O
NS O
) O
enhanced O
the O
latency O
of O
seizures O
induced O
by O
picrotoxin B
in O
mice O
. O

Intraperitoneal O
administration O
of O
cholecystokinin B
octapeptide I
sulphate O
ester O
( O
CCK B
- I
8 I
- O
SE O
) O
and O
nonsulphated O
cholecystokinin B
octapeptide I
( O
CCK B
- I
8 I
- O
NS O
) O
enhanced O
the O
latency O
of O
seizures O
induced O
by O
picrotoxin B
in O
mice O
. O

Atrial O
thrombosis O
involving O
the O
heart O
of O
F O
- O
344 O
rats O
ingesting O
quinacrine B
hydrochloride I
. O

Quinacrine B
hydrochloride I
is O
toxic O
for O
the O
heart O
of O
F O
- O
344 O
rats O
. O

Rats O
treated O
with O
500 O
ppm O
quinacrine B
hydrochloride I
in O
the O
diet O
all O
developed O
a O
high O
incidence O
of O
left O
atrial O
thrombosis O
. O

Seventy O
percent O
of O
rats O
given O
250 O
ppm O
quinacrine B
hydrochloride I
and O
1 O
, O
000 O
ppm O
sodium B
nitrite I
simultaneously O
in O
the O
diet O
had O
thrombosis O
of O
the O
atria O
of O
the O
heart O
, O
while O
untreated O
control O
rats O
in O
this O
laboratory O
did O
not O
have O
atrial O
thrombosis O
. O

Seventy O
percent O
of O
rats O
given O
250 O
ppm O
quinacrine B
hydrochloride I
and O
1 O
, O
000 O
ppm O
sodium B
nitrite I
simultaneously O
in O
the O
diet O
had O
thrombosis O
of O
the O
atria O
of O
the O
heart O
, O
while O
untreated O
control O
rats O
in O
this O
laboratory O
did O
not O
have O
atrial O
thrombosis O
. O

Sodium B
nitrite I
in O
combination O
with O
quinacrine B
hydrochloride I
appeared O
to O
have O
no O
additional O
effect O
. O

Sodium B
nitrite I
in O
combination O
with O
quinacrine B
hydrochloride I
appeared O
to O
have O
no O
additional O
effect O
. O

A O
69 O
- O
yr O
- O
old O
man O
, O
who O
was O
concurrently O
being O
treated O
with O
pilocarpine B
nitrate I
and O
timolol B
maleate I
eye O
drops O
, O
developed O
a O
bradycardia O
and O
became O
hypotensive O
during O
halothane B
anaesthesia O
. O

A O
69 O
- O
yr O
- O
old O
man O
, O
who O
was O
concurrently O
being O
treated O
with O
pilocarpine B
nitrate I
and O
timolol B
maleate I
eye O
drops O
, O
developed O
a O
bradycardia O
and O
became O
hypotensive O
during O
halothane B
anaesthesia O
. O

Coronary O
blood O
flow O
, O
cardiac O
work O
and O
metabolism O
were O
studied O
in O
dogs O
under O
sodium B
nitroprusside I
( O
SNP B
) O
and O
trimetaphan B
( O
TMP B
) O
deliberate O
hypotension O
( O
20 O
% O
and O
40 O
% O
mean O
pressure O
decrease O
from O
baseline O
) O
. O

A O
case O
of O
nontraumatic O
dissecting O
aneurysm O
of O
the O
basilar O
artery O
in O
association O
with O
hypertension O
, O
smoke O
, O
and O
oral B
contraceptives I
is O
reported O
in O
a O
young O
female O
patient O
with O
a O
locked O
- O
in O
syndrome O
. O

Cardiovascular O
effects O
of O
hypotension O
induced O
by O
adenosine B
triphosphate I
and O
sodium B
nitroprusside I
on O
dogs O
with O
denervated O
hearts O
. O

Cardiovascular O
effects O
of O
hypotension O
induced O
by O
adenosine B
triphosphate I
and O
sodium B
nitroprusside I
on O
dogs O
with O
denervated O
hearts O
. O

Adenosine B
triphosphate I
( O
ATP B
) O
and O
sodium B
nitroprusside I
( O
SNP B
) O
are O
administered O
to O
patients O
to O
induce O
and O
control O
hypotension O
during O
anesthesia O
. O

Adenosine B
triphosphate I
( O
ATP B
) O
and O
sodium B
nitroprusside I
( O
SNP B
) O
are O
administered O
to O
patients O
to O
induce O
and O
control O
hypotension O
during O
anesthesia O
. O

Comparative O
study O
: O
Endografine B
( O
diatrizoate B
) O
, O
Vasurix B
polyvidone I
( O
acetrizoate B
) O
, O
Dimer B
- I
X I
( O
iocarmate B
) O
and O
Hexabrix B
( O
ioxaglate B
) O
in O
hysterosalpingography O
. O

Side O
effects O
of O
hysterosalpingography O
with O
Dimer B
- I
X I
, O
Hexabrix B
, O
Vasurix B
polyvidone I
and O
Endografine B
in O
142 O
consecutive O
patients O
, O
receiving O
one O
of O
the O
four O
tested O
media O
were O
evaluated O
from O
replies O
to O
postal O
questionnaires O
. O

Hexabrix B
and O
Vasurix B
polyvidone I
are O
considered O
the O
best O
contrast B
media I
for O
hysterosalpingography O
and O
perhaps O
because O
of O
its O
low O
toxicity O
Hexabrix B
should O
be O
preferred O
. O

Hexabrix B
and O
Vasurix B
polyvidone I
are O
considered O
the O
best O
contrast B
media I
for O
hysterosalpingography O
and O
perhaps O
because O
of O
its O
low O
toxicity O
Hexabrix B
should O
be O
preferred O
. O

Two O
well O
- O
documented O
cases O
of O
bilateral O
retinal O
artery O
and O
choriocapillaris O
occlusions O
with O
blindness O
following O
head O
and O
neck O
soft O
- O
tissue O
injection O
with O
methylprednisolone B
acetate I
in O
combination O
with O
lidocaine B
, O
epinephrine B
, O
or O
penicillin B
are O
reported O
. O

Total O
blindness O
with O
a O
transient O
tonic O
pupillary O
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual O
- O
evoked O
potentials O
developed O
in O
a O
54 O
- O
year O
- O
old O
man O
after O
the O
use O
of O
quinine B
sulfate I
for O
leg O
cramps O
. O

An O
11 O
- O
year O
- O
old O
boy O
was O
given O
halothane B
, O
nitrous B
oxide I
and O
oxygen B
, O
pancuronium B
0 O
. O
4 O
mg O
and O
suxamethonium B
100 O
mg O
for O
induction O
of O
anaesthesia O
. O

Myopathy O
due O
to O
lack O
of O
vitamin B
E I
and O
myopathy O
induced O
by O
certain O
viruses O
have O
much O
in O
common O
anatomically O
and O
pathologically O
with O
the O
human O
form O
. O

The O
authors O
induced O
myodystrophy O
in O
the O
rat O
by O
giving O
it O
a O
diet O
lacking O
in O
vitamin B
E I
. O

The O
pharmacological O
characteristics O
of O
vitamin B
E I
and O
the O
degenerative O
changes O
brought O
about O
by O
its O
deficiency O
, O
especially O
in O
the O
muscles O
, O
are O
illustrated O
. O

The O
encouraging O
results O
obtained O
in O
various O
authoratative O
departments O
in O
myopathic O
patients O
by O
using O
anabolizing O
steroids B
have O
encouraged O
the O
authors O
to O
investigate O
the O
beneficial O
effects O
of O
one O
anabolizing O
agent O
( O
Dianabol B
, O
CIBA B
) O
at O
high O
doses O
in O
rats O
rendered O
myopathic O
by O
a O
diet O
deficient O
in O
vitamin B
E I
. O

The O
authors O
conclude O
by O
affirming O
the O
undoubted O
efficacy O
of O
the O
anabolizing O
steroids B
in O
experimental O
myopathic O
disease O
, O
but O
they O
have O
reservations O
as O
to O
the O
transfer O
of O
the O
results O
into O
the O
human O
field O
, O
where O
high O
dosage O
cannot O
be O
carried O
out O
continuously O
because O
of O
the O
effects O
of O
the O
drug O
on O
virility O
; O
because O
the O
tissue O
injury O
too O
often O
occurs O
at O
an O
irreversible O
stage O
vis O
- O
a O
- O
vis O
the O
" O
regeneration O
" O
of O
the O
muscle O
tissue O
; O
and O
finally O
because O
the O
dystrophic O
injurious O
agent O
is O
certainly O
not O
the O
lack O
of O
vitamin B
E I
but O
something O
as O
yet O
unknown O
. O

Soon O
after O
the O
introduction O
of O
ACE B
inhibitors I
, O
acute O
bouts O
of O
angio O
- O
oedema O
were O
reported O
in O
association O
with O
the O
use O
of O
these O
drugs O
. O

We O
wish O
to O
draw O
attention O
to O
the O
possibility O
of O
adverse O
reactions O
to O
ACE B
inhibitors I
after O
long O
- O
term O
use O
and O
in O
patients O
with O
pre O
- O
existing O
angio O
- O
oedema O
. O

Pharmacological O
studies O
on O
a O
new O
dihydrothienopyridine B
calcium I
antagonist O
, O
S B
- I
312 I
- I
d I
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
compare O
influence O
of O
central O
arginine B
vasopressin I
( O
AVP B
) O
and O
of O
atrial O
natriuretic O
peptide O
( O
ANP O
) O
on O
control O
of O
arterial O
blood O
pressure O
( O
MAP O
) O
and O
heart O
rate O
( O
HR O
) O
in O
normotensive O
( O
WKY O
) O
and O
spontaneously O
hypertensive O
( O
SHR O
) O
rats O
. O

Sensitivity O
of O
cardiac O
component O
of O
baroreflex O
( O
CCB O
) O
, O
expressed O
as O
a O
slope O
of O
the O
regression O
line O
was O
determined O
from O
relationships O
between O
systolic O
arterial O
pressure O
( O
SAP O
) O
and O
HR O
period O
( O
HRp O
) O
during O
phenylephrine B
( O
Phe B
) O
- O
induced O
hypertension O
and O
sodium B
nitroprusside I
( O
SN B
) O
- O
induced O
hypotension O
. O

This O
article O
presents O
a O
patient O
with O
hypoparathyroidism O
who O
was O
treated O
with O
calcium B
carbonate I
and O
calcitriol B
resulting O
in O
two O
admissions O
to O
the O
hospital O
for O
milk O
- O
alkali O
syndrome O
. O

Increased O
expression O
of O
neuronal O
nitric B
oxide I
synthase O
in O
bladder O
afferent O
pathways O
following O
chronic O
bladder O
irritation O
. O

Immunocytochemical O
techniques O
were O
used O
to O
examine O
alterations O
in O
the O
expression O
of O
neuronal O
nitric B
oxide I
synthase O
( O
NOS O
) O
in O
bladder O
pathways O
following O
acute O
and O
chronic O
irritation O
of O
the O
urinary O
tract O
of O
the O
rat O
. O

The O
effect O
of O
recombinant O
human O
insulin O
- O
like O
growth O
factor O
- O
I O
on O
chronic O
puromycin B
aminonucleoside I
nephropathy O
in O
rats O
. O

We O
recently O
demonstrated O
that O
recombinant O
hGH O
exacerbates O
renal O
functional O
and O
structural O
injury O
in O
chronic O
puromycin B
aminonucleoside I
( O
PAN B
) O
nephropathy O
, O
an O
experimental O
model O
of O
glomerular O
disease O
. O

These O
effects O
were O
not O
mediated O
by O
a O
dopaminergic O
mechanism O
as O
nefiracetam B
, O
at O
millimolar O
concentrations O
, O
failed O
to O
displace O
either O
[ O
3H O
] O
SCH B
23390 I
or O
[ O
3H O
] O
spiperone B
binding O
from O
D1 O
or O
D2 O
dopamine B
receptor O
subtypes O
, O
respectively O
. O

Population O
- O
based O
study O
of O
risk O
of O
venous O
thromboembolism O
associated O
with O
various O
oral B
contraceptives I
. O

BACKGROUND O
: O
Four O
studies O
published O
since O
December O
, O
1995 O
, O
reported O
that O
the O
incidence O
of O
venous O
thromboembolism O
( O
VTE O
) O
was O
higher O
in O
women O
who O
used O
oral B
contraceptives I
( O
OCs B
) O
containing O
the O
third O
- O
generation O
progestagens B
gestodene B
or O
desogestrel B
than O
in O
users O
of O
OCs B
containing O
second O
- O
generation O
progestagens B
. O

Paclitaxel B
, O
5 B
- I
fluorouracil I
, O
and O
folinic B
acid I
in O
metastatic O
breast O
cancer O
: O
BRE O
- O
26 O
, O
a O
phase O
II O
trial O
. O

5 B
- I
Fluorouracil I
plus O
folinic B
acid I
and O
paclitaxel B
( O
Taxol B
; O
Bristol O
- O
Myers O
Squibb O
Company O
, O
Princeton O
, O
NJ O
) O
are O
effective O
salvage O
therapies O
for O
metastatic O
breast O
cancer O
patients O
. O

We O
performed O
a O
phase O
II O
trial O
of O
paclitaxel B
175 O
mg O
/ O
m2 O
over O
3 O
hours O
on O
day O
I O
followed O
by O
folinic B
acid I
300 O
mg O
over O
1 O
hour O
before O
5 B
- I
fluorouracil I
350 O
mg O
/ O
m2 O
on O
days O
1 O
to O
3 O
every O
28 O
days O
( O
TFL O
) O
in O
women O
with O
metastatic O
breast O
cancer O
. O

A O
case O
of O
acute O
renal O
failure O
, O
due O
to O
occlusion O
of O
renal O
vessels O
in O
a O
patient O
with O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
treated O
with O
all B
- I
trans I
- I
retinoic I
acid I
( O
ATRA B
) O
and O
tranexamic B
acid I
has O
been O
described O
recently O
. O

The O
protective O
effect O
was O
prevalent O
among O
D B
- I
glucarates I
, O
and O
also O
to O
other O
saccharic B
acid I
, O
hexauronic B
acids I
and O
hexaaldonic B
acids I
, O
although O
to O
a O
lesser O
degree O
, O
but O
not O
to O
a O
hexaaldose O
, O
sugar B
alcohols I
, O
substances O
inthe O
TCA B
cycle O
and O
other O
acidic O
compounds O
. O

The O
protective O
effect O
was O
prevalent O
among O
D B
- I
glucarates I
, O
and O
also O
to O
other O
saccharic B
acid I
, O
hexauronic B
acids I
and O
hexaaldonic B
acids I
, O
although O
to O
a O
lesser O
degree O
, O
but O
not O
to O
a O
hexaaldose O
, O
sugar B
alcohols I
, O
substances O
inthe O
TCA B
cycle O
and O
other O
acidic O
compounds O
. O

The O
protective O
effect O
was O
prevalent O
among O
D B
- I
glucarates I
, O
and O
also O
to O
other O
saccharic B
acid I
, O
hexauronic B
acids I
and O
hexaaldonic B
acids I
, O
although O
to O
a O
lesser O
degree O
, O
but O
not O
to O
a O
hexaaldose O
, O
sugar B
alcohols I
, O
substances O
inthe O
TCA B
cycle O
and O
other O
acidic O
compounds O
. O

The O
protective O
effect O
was O
prevalent O
among O
D B
- I
glucarates I
, O
and O
also O
to O
other O
saccharic B
acid I
, O
hexauronic B
acids I
and O
hexaaldonic B
acids I
, O
although O
to O
a O
lesser O
degree O
, O
but O
not O
to O
a O
hexaaldose O
, O
sugar B
alcohols I
, O
substances O
inthe O
TCA B
cycle O
and O
other O
acidic O
compounds O
. O

METHODS O
AND O
RESULTS O
: O
In O
20 O
patients O
( O
14 O
men O
and O
6 O
women O
aged O
39 O
to O
72 O
years O
) O
referred O
for O
cardiac O
catheterization O
for O
the O
evaluation O
of O
chest O
pain O
, O
we O
measured O
heart O
rate O
, O
systemic O
arterial O
pressure O
, O
LV O
pressure O
and O
its O
first O
derivative O
( O
dP O
/ O
dt O
) O
, O
and O
LV O
volumes O
and O
ejection O
fraction O
before O
and O
during O
the O
final O
2 O
to O
3 O
minutes O
of O
a O
15 O
- O
minute O
intracoronary O
infusion O
of O
saline O
( O
n O
= O
10 O
, O
control O
subjects O
) O
or O
cocaine B
hydrochloride I
1 O
mg O
/ O
min O
( O
n O
= O
10 O
) O
. O

Sumatriptan B
succinate I
, O
a O
serotonin B
- O
1 O
( O
5 B
- I
hydroxytryptamine I
- O
1 O
) O
receptor O
agonist O
, O
is O
an O
antimigraine O
drug O
that O
is O
reported O
to O
act O
by O
selectively O
constricting O
intracranial O
arteries O
. O

Differential O
effects O
of O
17alpha B
- I
ethinylestradiol I
on O
the O
neutral O
and O
acidic O
pathways O
of O
bile B
salt I
synthesis O
in O
the O
rat O
. O

Effects O
of O
17alpha B
- I
ethinylestradiol I
( O
EE B
) O
on O
the O
neutral O
and O
acidic O
biosynthetic O
pathways O
of O
bile B
salt I
( O
BS B
) O
synthesis O
were O
evaluated O
in O
rats O
with O
an O
intact O
enterohepatic O
circulation O
and O
in O
rats O
with O
long O
- O
term O
bile O
diversion O
to O
induce O
BS B
synthesis O
. O

For O
this O
purpose O
, O
bile B
salt I
pool O
composition O
, O
synthesis O
of O
individual O
BS B
in O
vivo O
, O
hepatic O
activities O
, O
and O
expression O
levels O
of O
cholesterol B
7alpha O
- O
hydroxylase O
( O
CYP7A O
) O
, O
and O
sterol B
27 O
- O
hydroxylase O
( O
CYP27 O
) O
, O
as O
well O
as O
of O
other O
enzymes O
involved O
in O
BS B
synthesis O
, O
were O
analyzed O
in O
rats O
treated O
with O
EE B
( O
5 O
mg O
/ O
kg O
, O
3 O
days O
) O
or O
its O
vehicle O
. O

This O
study O
shows O
that O
17alpha B
- I
ethinylestradiol I
( O
EE B
) O
- O
induced O
intrahepatic O
cholestasis O
in O
rats O
is O
associated O
with O
selective O
inhibition O
of O
the O
neutral O
pathway O
of O
bile B
salt I
( O
BS B
) O
synthesis O
. O

The O
effects O
of O
helodermin B
, O
a O
basic O
35 O
- O
amino B
acid I
peptide O
isolated O
from O
the O
venom O
of O
a O
lizard O
salivary O
gland O
, O
on O
arterial O
blood O
pressure O
and O
heart O
rate O
were O
examined O
in O
the O
rat O
, O
focusing O
on O
the O
possibility O
that O
activation O
of O
ATP B
sensitive O
K B
+ O
( O
K B
( O
ATP B
) O
) O
channels O
is O
involved O
in O
the O
responses O
. O

EDRF O
( O
endothelium O
- O
derived O
relaxing O
factor O
) O
/ O
nitric B
oxide I
does O
not O
seem O
to O
play O
an O
important O
role O
in O
the O
peptide O
- O
produced O
hypotension O
. O

Long O
- O
term O
efficacy O
and O
adverse O
event O
of O
nifedipine B
sustained O
- O
release O
tablets O
for O
cyclosporin B
A I
- O
induced O
hypertension O
in O
patients O
with O
psoriasis O
. O

Thirteen O
psoriatic O
patients O
with O
hypertension O
during O
the O
course O
of O
cyclosporin B
A I
therapy O
were O
treated O
for O
25 O
months O
with O
a O
calcium B
channel O
blocker O
, O
sustained O
- O
release O
nifedipine B
, O
to O
study O
the O
clinical O
antihypertensive O
effects O
and O
adverse O
events O
during O
treatment O
with O
both O
drugs O
. O

Seven O
of O
the O
13 O
patients O
had O
exhibited O
a O
subclinical O
hypertensive O
state O
before O
cyclosporin B
A I
therapy O
. O

The O
adverse O
events O
during O
combined O
therapy O
with O
cyclosporin B
A I
and O
nifedipine B
included O
an O
increase O
in O
blood B
urea I
nitrogen I
levels O
in O
9 O
of O
the O
13 O
patients O
and O
development O
of O
gingival O
hyperplasia O
in O
2 O
of O
the O
13 O
patients O
. O

Our O
findings O
indicate O
that O
sustained O
- O
release O
nifedipine B
is O
useful O
for O
hypertensive O
psoriatic O
patients O
under O
long O
- O
term O
treatment O
with O
cyclosporin B
A I
, O
but O
that O
these O
patients O
should O
be O
monitored O
for O
gingival O
hyperplasia O
. O

